Drug intelligence / Profile preview

1910-102

Development stage: Preclinical
Lead developer: 1910 Genetics
Modality: Small Molecules

Overview

**1910-102** is a covalent small molecule inhibitor developed by 1910 Genetics for **precision neuroscience**, specifically targeting **post-surgical pain**. It represents a non-opioid approach to chronic pain management, discovered using the company's AI-driven platform CANDID-CNS™, which integrates computational modeling, wet lab automation, and multimodal AI to design novel therapeutics. The program has received partial funding support, highlighting its potential in addressing unmet needs in pain therapy through covalent binding mechanisms that enable prolonged target engagement.[1][2]

Beyond the preview

Go deeper on 1910-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1910-102.

Explore the full profile